What compels a scientist to leave academia for the high-stakes world of finance and then become the CEO of a publicly-traded biotech company?In this episode of Oxford+, host Susannah de Jager sits down with Zandy Forbes, the CEO and co-founder of MeiraGTx.
Zandy shares her fascinating career journey, explaining how her experience as a hedge fund analyst shaped her unique approach to building a resilient, multi-asset genetic medicine company.They discuss MeiraGTx's pioneering work, from developing a mind-blowing technology that turns the body into a drug manufacturing facility to their successful clinical trials that are changing the lives of patients with inherited blindness, Parkinson’s, and other diseases.
Zandy Forbes: The CEO and co-founder of MeiraGTx, a NASDAQ-listed clinical-stage genetic medicine company. She holds a double first in Natural Sciences from Cambridge University and a PhD in Molecular Genetics from the University of Oxford. Before co-founding MeiraGTx in 2015, she spent over a decade as an analyst and portfolio manager at a healthcare-focused hedge fund.